323 related articles for article (PubMed ID: 17668426)
1. Targeting vasculature in urologic tumors: mechanistic and therapeutic significance.
Sakamoto S; Ryan AJ; Kyprianou N
J Cell Biochem; 2008 Feb; 103(3):691-708. PubMed ID: 17668426
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of disease: angiogenesis in urologic malignancies.
Charlesworth PJ; Harris AL
Nat Clin Pract Urol; 2006 Mar; 3(3):157-69. PubMed ID: 16528288
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases.
Fallah A; Sadeghinia A; Kahroba H; Samadi A; Heidari HR; Bradaran B; Zeinali S; Molavi O
Biomed Pharmacother; 2019 Feb; 110():775-785. PubMed ID: 30554116
[TBL] [Abstract][Full Text] [Related]
4. The role of angiogenesis in prostate and other urologic cancers: a review.
Izawa JI; Dinney CP
CMAJ; 2001 Mar; 164(5):662-70. PubMed ID: 11258215
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis and prostate cancer tumor growth.
Nicholson B; Theodorescu D
J Cell Biochem; 2004 Jan; 91(1):125-50. PubMed ID: 14689586
[TBL] [Abstract][Full Text] [Related]
6. Microvessel density and angiogenic promoters in relation to metastatic urological carcinoma. Is there a difference between lymph node and more distant metastases subgroups?
Morgan DR; Gregg KL
Histopathology; 2002 Aug; 41(2):170-1. PubMed ID: 12147096
[No Abstract] [Full Text] [Related]
7. Advances in angiogenesis research: relevance to urological oncology.
Campbell SC
J Urol; 1997 Nov; 158(5):1663-74. PubMed ID: 9334575
[TBL] [Abstract][Full Text] [Related]
8. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis in prostate cancer: biology and therapeutic opportunities.
Nicholson B; Schaefer G; Theodorescu D
Cancer Metastasis Rev; 2001; 20(3-4):297-319. PubMed ID: 12085968
[TBL] [Abstract][Full Text] [Related]
10. Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting.
Reynolds AR; Kyprianou N
Br J Pharmacol; 2006 Feb; 147 Suppl 2(Suppl 2):S144-52. PubMed ID: 16465179
[TBL] [Abstract][Full Text] [Related]
11. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis and hematological malignancies.
Lim ST; Levine AM
Hematology; 2005 Feb; 10(1):11-24. PubMed ID: 16019441
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.
Bender RJ; Mac Gabhann F
BMC Syst Biol; 2015 Sep; 9():55. PubMed ID: 26341082
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.
Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
Lasers Surg Med; 2011 Sep; 43(7):651-62. PubMed ID: 22057493
[TBL] [Abstract][Full Text] [Related]
15. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
16. Tumor vasculature: the Achilles' heel of cancer?
Johannessen TC; Wagner M; Straume O; Bjerkvig R; Eikesdal HP
Expert Opin Ther Targets; 2013 Jan; 17(1):7-20. PubMed ID: 23121690
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic approaches for targeting tumor angiogenesis.
Linkous AG; Yazlovitskaya EM
Anticancer Res; 2012 Jan; 32(1):1-12. PubMed ID: 22213282
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
19. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
[TBL] [Abstract][Full Text] [Related]
20. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications.
Harper J; Moses MA
EXS; 2006; (96):223-68. PubMed ID: 16383021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
